MANAGEMENT OF CROHNS-DISEASE - NEW THERAPEUTIC APPROACHES

被引：0
作者：
RACHMILEWITZ, D
机构：
[1] Department of Medicine, Hadassah University Hospital, Jerusalem
来源：
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 1994年 / 6卷 / 02期
关键词：
FREE RADICALS; PLATELET-ACTIVATING FACTOR; SOMATOSTATIN; KETOTIFEN; NITROXIDES;
D O I：
10.1097/00042737-199402000-00003
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
As long as the etiology of Crohn's disease is unknown, the development of new therapeutic modalities should take the increased understanding of the pathogenesis of the disease into consideration. Modulation of inflammatory mediators with specific lipoxygenase inhibitors or with specific platelet-activating factor receptor antagonists may be of value. Drugs such as ketotifen and synthetic somatostatin analogues, which inhibit the release of mediators from inflammatory cells, may be of benefit in view of their antisecretory and anti-inflammatory effects. The crucial role of free radicals in the pathogenesis of tissue injury advocates trial with potent scavengers, such as nitroxides, whereas there is still a place for further trials with antimycobacterial therapy.
引用
收藏
页码：108 / 112
页数：5
相关论文
共 30 条
[21]  
Grosman I., Simon D., Potential use of somatostatin and itssynthetic analogue, octreotide, Am J Gastroenterol, 85, pp. 1061-1072, (1990)
[22]  
Grisham M.B., Granger D.N., Neutrophil mediated mucosalinjur-role of reactive oxygen metabolites, Dig Dis Sci, 33, pp. 6S-15S, (1988)
[23]  
Rachmilewitz D., Stamler J.S., Karmeli F., Mullins M.E., Singel D., Loscalzo J., Et al., Eroxynitrite induced rat colitis a new model of colonic inflammation, Gastroenterology, (1994)
[24]  
Rachmilewitz D., Stamler J.S., Bachwich D., Karmeli F., Z A., Loscalzo J., Et al., Enhanced colonic nitric oxide generation and stimulated nitric oxide synthase activity in experimental colitis and in active inflammatory bowel disease [abstract], Gastroenterology, 104, (1993)
[25]  
Allgayer H., Clinical relevance of oxygen radicals in inflam-matory bowel disease — facts and fashion, Klin Wochenschr, 69, pp. 1001-1003, (1991)
[26]  
Rachmilewitz D., Karmeli F., Euakim R., Samuni A., Nitroxides a novel approach to decrease propagation of damage in the upper and lower gastrointestinal tract [abstract], Dig Dis Sci, 38, (1993)
[27]  
Chiodini R.J., Crohn’s disease and the mycobacterioses: A re-view and comparison of two disease entities, Clin Microbiol Rev, 2, pp. 90-117, (1989)
[28]  
Thayer W.R., Couta J.A., Chiodini R.J., Van Kruningen H.J., Use of rifabutin and streptomycin in the therapy of Crohn’s disease [abstract], Gastroenterology, 94, (1988)
[29]  
Parker M.C., Savagmutter S.H., McFadden J.J., Herman Taylor J., Results of quadruple antimycobacterial chemotherapy in17 Crohn’s disease patients completing six months treatment [abstract], Gastroenterology, 94, (1988)
[30]  
Kohn A., Prantera C., Mangiarotti R., Luzi C., Reoli A., Antimycobacterial therapy and Crohn’s disease: A randomized placebo controlled trial [abstract], Gastroenterology, 102, (1992)
123